Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Add filters

Year range
Article in Chinese | WPRIM | ID: wpr-884559


Objective:To investigate the effect of miR-424-5p on radiosensitivity and its mechanism in cervical cancer patients.Methods:The expression levels of miR-424-5p in the cervical cancer tissues and Hela cells were detected by RT-qPCR. The apoptosis rate of Hela cells was determined by flow cytometry. The proliferation activity of Hela cells was detected by CCK-8 assay. The protein expression levels in Hela cells were measured by Western blot.Results:Compared with normal tissues and cells, the expression level of miR-424-5p was significantly down-regulated in the cervical cancer tissues and Hela cells (1.03 vs. 0.88, P<0.01; 1.00 vs. 0.75, P<0.01). Overexpression of miR-424-5p significantly inhibited the proliferation activity of Hela cells after radiation treatment ( P<0.01), and significantly increased the apoptosis rate of Hela cells after radiation treatment (24.82% vs. 49.94%, P<0.001). Overexpression of miR-424-5p inhibited HMGA1 expression (1.01 vs. 0.63, P<0.01). miR-424-5p directly affected HMGA1, thereby impacting the radiosensitivity of cervical cancer radiotherapy. Conclusion:miR-424-5p can improve the radiosensitivity of cervical cancer radiotherapy by directly targeting HMGA1.

China Pharmacy ; (12): 2046-2049, 2017.
Article in Chinese | WPRIM | ID: wpr-609830


OBJECTIVE:To observe therapeutic efficacy and safety of nedaplatin combined with paclitaxel in the treatment of advanced cervical cancer. METHODS:Totally 100 patients with advanced cervical cancer were randomly divided into observation group(50 cases)and control group(50 cases). Both groups were given 6MV linear accelerator radiotherapy combined with intra-cavitary irradiation. Based on it,control group was additionally given Cisplatin injection 20 mg/m2,d1+Paclitaxel injection 35 mg/m2,d1 intravenously within 3 h. Observation group was additionally given Nedaplatin for injection 20 mg/m2,d1+Paclitaxel injection intravenously(same usage and dosage as control group). A treatment course lasted for a week,and both groups received 6 courses of treatment. Short-term efficacies of 2 groups were observed,and the levels of vascular endothelial growth factor A(VEGF-A), VEGF-C and VEGF-D,lymphatic microvessel density(LVD),microvessel density(MVD),toxic reaction were also observed be-fore and after treatment. RESULTS: Total response rate(52.00% vs. 32.00%)and disease control rate(86.00% vs. 66.00%)of ob-servation group were significantly higher than those of control group,with statistical significance(P<0.05). After treatment,the levels of VEGF-A,VEGF-C and VEGF-D,LVD,MVD in 2 groups were significantly lower than before treatment,and the obser-vation group was significantly lower than the control group,with statistical significance(P<0.05). The incidence of thrombocyto-penia in observation group was significantly higher than control group,and the incidence of nausea and vomiting was significantly lower than control group,with statistical significance(P<0.05). CONCLUSIONS: Nedaplatin combined with paclitaxel can im-prove short-term efficacy of patients with advanced cervical cancer,reduce gastrointestinal reaction,VEGF level and inhibit the generation of tumor vessel,but great importance should be attached to platelet toxic reaction.

Article in Chinese | WPRIM | ID: wpr-392011


Reverse transcription-PCR and methylation-specific PCR (MSP) were used to determine the expression levels of Syk gene and the methylation status of its promoter in tissue samples from 60 patients with cervical cancer, 50 patients with cervical intraepithelial neoplasia (CIN), and 20 normal controls. We also analyzed the association of the methylation status and expression levels of Syk gene with linicopathological features of patients. The expression rates of Syk gene in 20 normal cervical tissue samples and 18 CIN Ⅰ samples were both 100% ; those of CIN Ⅱ- Ⅲ and cervical carcinoma were 56% (18/32)and 35% (21/60) respectively. Among cervical carcinoma patients, the expression of Syk mRNA was detected in one out of 13 cases with lymph node metastasis (1/13) and in 20 out of 47 cases with no lymph node metastasis (43%). The methylation of Syk gene in promoter region was detected in 34 out of 60 cases of cervical carcinoma (57%) ; while there was no methylation in CIN cases. In 13 cases with lymph node metastasis, 11 were found to have the methylation of Syk gene. The methylation rate of Syk promoter in cervical carcinoma was higher than that of CIN tissue( x~2 = 7. 13, P <0. 01 ). The methylation status of Syk gene was correlated with the lymph node metastasis ( P< 0. 05 ), but not with other clinicopathological parameters ( P > 0. 05). There was a significant correlation between methylation status and expression level of Syk gene ( P < 0. 05 ). The hypermethylation leads to silencing of the Syk gene in human cervicalcarcinoma. Syk hypermethylation may be associated with oncngenesis, metastasis of cervical carcinoma.